ADMA Biologics Inc
NASDAQ:ADMA
ADMA Biologics Inc
Accounts Payable
ADMA Biologics Inc
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADMA Biologics Inc
NASDAQ:ADMA
|
Accounts Payable
$17.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
26%
|
CAGR 10-Years
20%
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$622m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$351.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$671.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
35%
|
See Also
What is ADMA Biologics Inc's Accounts Payable?
Accounts Payable
17.2m
USD
Based on the financial report for Mar 31, 2024, ADMA Biologics Inc's Accounts Payable amounts to 17.2m USD.
What is ADMA Biologics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
20%
Over the last year, the Accounts Payable growth was 32%. The average annual Accounts Payable growth rates for ADMA Biologics Inc have been 12% over the past three years , 26% over the past five years , and 20% over the past ten years .